On Monday, December 15, the USPTO issued its long awaited revision of the March 4, 2014 Myriad-Mayo Guidance: the 2014 Interim Guidance on Patent Subject Matter Eligibility, which not only supercedes the March 4, 2014 Myriad-Mayo Guidance, but also supplements the June 25, 2014 Preliminary Examination Instructions of the Supreme Court decision in Alice Corp. Overall, the Guidance is a substantial modification of the March 4 Myriad-Mayo Guidance. The USPTO has jettisoned the complicated factor test, and appears to have attempted to stay closer to the case law. It has included a series of new examples, relating to what it terms “nature-based products,” and promises to provide more. The examples seem designed to address some of the issues and concerns raised by the public regarding claiming inventions involving natural products. Notably absent are examples relating to medical diagnostic technology. While the 2014 Interim Guidance, appears to be more flexible and provides a less complicated framework to argue against Section 101 rejections than the March 4, 2014 Myriad-Mayo Guidance, it is still more restrictive than what the USPTO had been operating under prior to the Myriad, Mayo and Alice decisions, especially for inventions in the biotech area and should be reviewed closely to determine its implications. The USPTO will be accepting comments until March 15, 2015 and will hold a public forum on January 21, 2015.